Publication | Open Access

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

Phase 3Gastrointestinal OncologyMedicinePathologyColorectal CancerCancer TreatmentTribe StudyOncologyRadiation OncologyMolecular OncologyBevacizumab Versus Folfiri